Dataset Information

NOTCH2NLA silencing inhibits ovarian carcinoma progression and oncogenic activity in vivo and in vitro.

ABSTRACT:

Background

Among all gynecological malignancies, ovarian cancer (OC) is prone to recurrence, metastasis, and resistance, and has the highest mortality rate. Furthermore, China is about to face the risk of increased incidence of the disease. This study aimed to identify potential novel tumorigenesis and prognostic genes in OC.

Methods

The Genotype-Tissue Expression (GTEx) project and The Cancer Genome Atlas (TCGA) project were used to obtain mRNA sequencing datasets and clinical information to identify candidate genes critical to OC carcinogenesis and progression. The potential genes affecting OC were performed by comprehensive survival analysis, followed by external validation. Cell proliferation, wound healing, and transwell assays validated the effects of a potential gene on proliferation, migration, and invasion in the A2780 cell line. Observe xenograft formation in nude mice and use immunohistochemistry to determine the expression of epithelial-mesenchymal transition (EMT)-related proteins in xenograft tumors after gene silencing. Two-tailed Student's t-tests were used for two-group comparisons in in vivo and in vitro experiments.

Results

The current study developed an eight-gene model for predicting the survival of patients with OC, in which PI3, CCDC80, IL27RA, HERC1, and NOTCH2NLA represented adverse, HMGB3, CXCL11, and CXCL9 represented protective prognosis. Further, repression of NOTCH2NLA, the selected potential gene, blocked the proliferation, migration, and invasion of A2780 cells in vitro and inhibited the growth of xenograft tumors in vivo. Finally, we revealed that the expression of NOTCH2NLA in OC negatively correlated with that of E-cadherin and positively correlated with that of vimentin and SNAI2.

Conclusions

The study provided a novel view on the biological significance and function of NOTCH2NLA and confirmed that NOTCH2NLA plays a significant role in OC prognosis by affecting EMT, which could be used as a new biomarker for OC prognosis.

SUBMITTER: Guo W

PROVIDER: S-EPMC8667152 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

<i>NOTCH2NLA</i> silencing inhibits ovarian carcinoma progression and oncogenic activity <i>in vivo</i> and <i>in vitro</i>.

Guo Wendi W Sun Zhen Z Zhao Nannan N Zhou Yiwen Y Ren Jie J Huang Lingling L Ping Yi Y

Annals of translational medicine 20211101 22

<h4>Background</h4>Among all gynecological malignancies, ovarian cancer (OC) is prone to recurrence, metastasis, and resistance, and has the highest mortality rate. Furthermore, China is about to face the risk of increased incidence of the disease. This study aimed to identify potential novel tumorigenesis and prognostic genes in OC.<h4>Methods</h4>The Genotype-Tissue Expression (GTEx) project and The Cancer Genome Atlas (TCGA) project were used to obtain mRNA sequencing datasets and clinical in ...[more]

PMID: 34988178

Similar Datasets

Project description:BackgroundRecent studies have identified that circular RNAs (circRNAs) have an important role in cancer via their well-recognized sponge effect on miRNAs, which regulates a large variety of cancer-related genes. However, only a few circRNAs have been well-studied in renal cell carcinoma (RCC) and their regulatory function remains largely elusive.MethodsBioinformatics approaches were used to characterize the differentially expressed circRNAs in our own circRNA-sequencing dataset, as well as two public circRNA microarray datasets. CircNTNG1 (hsa_circ_0002286) was identified as a potential tumor-suppressing circRNA. Transwell assay and CCK-8 assay were used to assess phenotypic changes. RNA pull-down, luciferase reporter assays and FISH experiment were used to confirm the interactions among circNTNG1, miR-19b-3p, and HOXA5 mRNA. GSEA was performed to explore the downstream pathway regulated by HOXA5. Immunoblotting, chromatin immunoprecipitation, and methylated DNA immunoprecipitation were used to study the mechanism of HOXA5.ResultsIn all three circRNA datasets, circNTNG1, which was frequently deleted in RCC, showed significantly low expression in the tumor group. The basic properties of circNTNG1 were characterized, and phenotype studies also demonstrated the inhibitory effect of circNTNG1 on RCC cell aggressiveness. Clinically, circNTNG1 expression was associated with RCC stage and Fuhrman grade, and it also served as an independent predictive factor for both OS and RFS of RCC patients. Next, the sponge effect of circNTNG1 on miR-19b-3p and the inhibition of HOXA5 by miR-19b-3p were validated. GSEA analysis indicated that HOXA5 could inactivate the epithelial-mesenchymal transition (EMT) process, and this inactivation was mediated by HOXA5-induced SNAI2 (Slug) downregulation. Finally, it was confirmed that the Slug downregulation was caused by HOXA5, along with the DNA methyltransferase DNMT3A, binding to its promoter region and increasing the methylation level.ConclusionsBased on the experimental data, in RCC, circNTNG1/miR-19b-3p/HOXA5 axis can regulate the epigenetic silencing of Slug, thus interfering EMT and metastasis of RCC. Together, our findings provide potential biomarkers and novel therapeutic targets for future study in RCC.

Project description:BackgroundSerine hydroxymethyltransferase 2 (SHMT2) is a vital metabolic enzyme in one carbon metabolism catalyzing the conversion of serine to glycine, which has been reported to play a crucial role in the progression of tumors. However, its function in tongue squamous cell carcinoma (TSCC) remains unclear.MethodsSHMT2 expression was analyzed using samples in online databases, and was assessed through immunohistochemistry staining of collected clinical specimens. The correlation between SHMT2 expression and the cell cycle was predicted through bioinformatic analysis, including weighted gene co-expression network analysis (WGCNA) and gene set enrichment analysis (GSEA). After transfection with siRNA, CCK8 assay, Edu staining, flow cytometry, trans-well assay, and wound healing experiments were performed to verify the functional role of SHMT2 in vitro. A stable cell line with SHMT2 silencing was established to detect the oncogenic function of SHMT2 in vivo.ResultsThe expression of SHMT2 was up-regulated in TSCC tissues and cell lines compared with normal groups, and highly expressed SHMT2 significantly indicated a poorer clinical outcome for TSCC patients. Bioinformatic analysis found that high expression of SHMT2 was closely related with biologic process including cell cycle and cell cycle G1/S transition. Down regulating of SHMT2 significantly suppressed the proliferation, invasive and migrative ability of TSCC cells, and induced the prolongation of the G1 phase of the cell cycle in vitro. Furthermore, western blot showed that cell cycle-related regulators such as cyclin-dependent kinase 4 (CDK4) and cyclinD1 expression levels were decreased, while the expression levels of the cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 were increased after SHMT2 knockdown. Silencing SHMT2 in the HN6 cell line using short hairpin RNA also impeded tumor growth in vivo.ConclusionsOverexpression of SHMT2 in TSCC indicated low survival rates, and was associated with aggressive behaviors of TSCC. It was also found to be involved in cell cycle regulation of TSCC cells. SHMT2 may serve as a novel prognostic indicator of TSCC.

Project description:BackgroundIntegrin β6 (ITGB6), a key submonomer of integrin αvβ6, plays an important role in epithelial-to-mesenchymal transition (EMT), wound healing, epithelial-derived tumor growth, fibrosis, and epithelial repair. However, the role of ITGB6 in cervical carcinoma (CC) remains elusive.MethodsThe expression levels of ITGB6 in CC tissues and cell lines were determined using quantitative real-time polymerase chain reaction (qRT-PCR). The cell viability, proliferation, apoptosis, migration, and invasion were evaluated by Cell Counting Kit-8 (CCK-8), colony-forming, flow cytometry, and Transwell assay, respectively. The expression of related proteins, including EMT markers and the Janus kinase/signal transducer and activator of transcription (JAK/STAT3) signaling markers, were detected using western blotting.ResultsThe ITGB6 expression in CC tissues and cells (C-33A, Hela, SiHa, and Caski) was remarkably higher than that in paracarcinoma tissues and ECT1/E6E7 cells. The data from The Cancer Genome Atlas (TCGA) data set suggested that patients with CC with high ITGB6 expression showed poorer overall survival (OS). Compared with the empty transfection group (si-NC), si-ITGB6 restrained the proliferation, migration, and invasion of SiHa and Hela cells, while promoting cell apoptosis. si-ITGB6 suppression decreased the expression of Snail, vimentin, and N-cadherin, while increasing E-cadherin expression. Further research showed that si-ITGB6 reduced p-JAK1/JAK1, p-JAK2/JAK2, and p-STAT3/STAT3 expression in the JAK/STAT3 signaling pathway. Interestingly, proliferation, migration, invasion, and the expressions of the molecular markers of the JAK/STAT3 signaling pathway and EMT pathway induced by ITGB6 were altered by RO8191 (JAK/STAT3 pathway activator). Furthermore, the protein expression levels of Snail, vimentin, N-cadherin, p-STAT3/STAT3, p-JAK1/JAK1, and p-JAK2/JAK2 in tumor tissues were higher than those in adjacent normal tissue, while the expression level of E-cadherin was downregulated in tumor tissues.ConclusionsSilencing of ITGB6 restrains cell proliferation, migration and invasion, and promotes apoptosis in CC by inhibiting JAK/STAT signaling pathways. Thus, ITGB6 may perhaps be a new and useful candidate target for treating CC.